The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-22 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
The second, symbol s, is defined by taking the fixed numerical value of the caesium frequency, ΔνCs, the unperturbed ground-state hyperfine transition frequency of the caesium-133 atom, to be 9192631770 Hz, which is equal to s−1.
== Genomics == The gene is located on long arm of chromosome 11 (11q13) between base pairs 64,570,985 and 64,578,765. It has 10 exons and encodes a 610-amino acid protein. Over 1300 mutations have been reported to date (2010). The majority (>70%) of these are predicted to lead to truncated forms are scattered throughout the gene. Four - c.249_252delGTCT (deletion at codons 83-84), c.1546_1547insC (insertion at codon 516), c.1378C>T (Arg460Ter) and c.628_631delACAG (deletion at codons 210-211) have been reported to occur in 4.5%, 2.7%, 2.6% and 2.5% of families.
=== Portrait === The haircut is made up of divided, thick strands of hair, with a strand directly over the middle of Augustus's forehead framed by other strands over it. From the left two strands stray onto the forehead, and from the right three strands, a hairstyle first found on this statue. This hairstyle also marks the statue as being one of Augustus from comparison with his portrait on his coinage, which can also date it. This particular hairstyle is used as the first sign identifying this portrait type of Augustus as the Prima Porta type, the second and most popular of three official portrait types: other hairstyles of Augustus may be seen on the Ara Pacis, for example. Another full-size statue of Augustus with these "Primaporta type" features is the Augustus of Via Labicana, portraying Augustus in the role of Pontifex Maximus, now in the Museo Nazionale Romano. The face is idealized, but not like those of Polykleitos' statues. Augustus's face is not smoothed and shows details to indicate his individual features. Art underwent important changes during Augustus's reign, with the extreme realism that dominated art of the Republican era giving way to Greek influence, as seen in the portraits of the emperors – idealizations that summarized all the virtues Roman society held should be possessed by the exceptional man worthy of governing the Empire. In earlier portraits, Augustus allowed himself to be portrayed in monarchical fashion, but amended these with later more diplomatic images that represented him as "primus inter pares".
2,6-Dichlorophenolindophenol (DCPIP, DCIP or DPIP) is a chemical compound used as a redox dye. When oxidized, DCPIP is blue with a maximal absorption at 600 nm; when reduced, DCPIP is colorless. DCPIP can be used to measure the rate of photosynthesis and is an example of a Hill reagent. When exposed to light in a photosynthetic system, the dye is decolorised by chemical reduction. DCPIP has a higher affinity for electrons than ferredoxin and the photosynthetic electron transport chain can reduce DCPIP as a substitute for NADP+, that is normally the final electron carrier in photosynthesis. As DCPIP is reduced and becomes colorless, the resultant increase in light transmittance can be measured using a spectrophotometer.
=== Atmosphere of Mars === In 2013, OH near-infrared spectra were observed in the night glow in the polar winter atmosphere of Mars by use of the Compact Reconnaissance Imaging Spectrometer for Mars (CRISM).
Sources: en.wikipedia.org
Cantrell refused to comment on the singer's appearance, and band manager Susan Silver said she had not seen him since "last year". Staley made his final public appearance on October 31, 1998, when he attended a Jerry Cantrell solo concert in Seattle. He declined Cantrell's request to sing with him on stage. A photo taken of Staley backstage at this show is the most recent photo of him that has been publicly released. Thereafter, Staley was thought to have left behind his "self-imposed rock & roll exile", when in November 1998 he laid down additional vocal tracks as part of a supergroup called Class of '99, featuring members of Rage Against the Machine, Jane’s Addiction, and Porno for Pyros. On July 19, 1999, the radio program Rockline was hosting Cantrell, Inez, and Kinney for a discussion on the release of Nothing Safe: Best of the Box, when, unexpectedly, Staley called in to participate. This was Staley's last interview. From 1999 to 2002, Staley became more reclusive and depressed, rarely leaving his Seattle condo; little is known about the details of his life during this period. Staley was rumored to spend most of his days creating art, playing video games, or nodding off on drugs. Staley's one-time roommate and friend Morgen Gallagher later said that around 2001 Staley said he was asked to audition for Audioslave; this claim was later debunked by Audioslave guitarist Tom Morello.
1P-LSD, also known as 1-propionyl-LSD, is a psychedelic drug of the lysergamide family related to LSD. It is an amide derivative of LSD and a homologue of ALD-52 (1A-LSD). The drug originated in 2015 when it appeared as a designer drug sold online. It was first synthesized as a legal LSD alternative by Lizard Labs, a Netherlands based research chemical laboratory. It modifies the LSD molecule by adding a propionyl group to the nitrogen atom of LSD's indole group and is a prodrug of LSD.
A hypobaric chamber, or altitude chamber, is a chamber used during aerospace or high terrestrial altitude research or training to simulate the effects of high altitude on the human body, especially hypoxia (low oxygen) and hypobaria (low ambient air pressure). Some chambers also control for temperature and relative humidity.
== History == In the mid-twentieth century, mumps infections among children were not viewed as a serious public health issue, but adult men may develop debilitating testicular inflammation, which posed particular difficulty among close-quartered soldiers during wartime. As a result, during World War II (1939–1945), the United States government targeted mumps for scientific research. The first experimental mumps vaccine was licensed in 1948; developed from inactivated virus, it only had short-term effectiveness. Improved vaccines became commercially available in the 1960s. In 1963, Maurice Hilleman of Merck & Co. took samples of the mumps virus from his daughter, who had contracted the disease; she became the namesake for the resulting Jeryl Lynn strain. Building on then-recent advances that had led to vaccines for polio and measles, the mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. Hilleman's work led to the first effective mumps vaccine, called Mumpsvax. Licensed in 1967, its four-year development set a record for fastest development of a new vaccine, a record later surpassed by the COVID-19 vaccine, which was developed in less than a year.
In America, there is an animal welfare organization called Rescue Ink, in which outlaw biker gang members volunteer to rescue animals in need and combat against people who commit animal cruelty, such as breaking up cockfighting rings, stopping the killing of stray cats, breaking up dog fighting rings, and rescuing pets from abusive owners. In the American prison system, prison gangs are often known to physically harm and even kill inmates who have committed such crimes as child murder, serial killing, pedophilia, hate crimes, domestic violence, and rape, and inmates who have committed crimes against the elderly, animals, the disabled, the poor and the less fortunate. In many minority communities and poor neighborhoods, residents often distrust law enforcement, as a result the gang syndicates often take over to "police" their neighborhoods by committing acts against people who had committed crimes such as bullying, muggings, home invasions, hate crimes, stalking, sexual assault, domestic violence and child molestation, as well as mediating disputes between neighbors. The ways that the gangs would punish such individuals could range from forced apologies, being threatened, being forced to return stolen objects, vandalizing property, arson, being forced to move, bombings, being assaulted or battered, kidnappings, false imprisonment, torture or being murdered.
Sources: en.wikipedia.org
=== Pulmonary function tests === Spirometry classically reveals a reduction in the vital capacity (VC) with either a proportionate reduction in airflows, or increased airflows for the observed vital capacity. The latter finding reflects the increased lung stiffness (reduced lung compliance) associated with pulmonary fibrosis, which leads to increased lung elastic recoil. Measurement of static lung volumes using body plethysmography or other techniques typically reveals reduced lung volumes (restriction). This reflects the difficulty encountered in inflating the fibrotic lungs. The diffusing capacity for carbon monoxide (DLCO) is invariably reduced in IPF and may be the only abnormality in mild or early disease. Its impairment underlies the propensity of patients with IPF to exhibit oxygen desaturation with exercise which can also be evaluated using the 6-minute walk test (6MWT). Terms such as 'mild', 'moderate', and 'severe' are sometimes used for staging disease and are commonly based on resting pulmonary function test measurements. However, there is no clear consensus regarding the staging of IPF patients and what are the best criteria and values to use. Mild-to-moderate IPF has been characterized by the following functional criteria:
== Development == Developed as a next generation aptamer technology, Optimer ligands were produced to improve the performance, manufacturability, and commercialisation of aptamers. Optimer ligands are selected via an automated, high throughput in vitro screening process. 3 distinct discovery platforms are integrated into the Optimer platform for optimized discovery according to target type. Starting from a diverse library of potential nucleic acid binders, the Optimer library is refined and enriched for sequences that have the required binding characteristics including affinity, specificity, cross reactivity, and buffer compatibility. The enriched Optimer population is subsequently screened to identify the best performing Optimer ligand sequence. Following selection of the appropriate sequence the identified Optimer undergoes a process to determine the minimum oligonucleotide fragment within this sequence that possesses the correct target-binding characteristics. The Optimer is trimmed to contain only this sequence, removing additional free non-target binding nucleotide bases. This reduces the molecular weight of the Optimer from 29 kDa to 5 kDa and increases the stability of the molecule through a reduction in entropy, as additional motion of the free nucleotides is removed.
As more and more members of Generation Z reached adulthood during the 2020s, voter turnouts in this cohort has been growing, even though young people are still less likely to vote than older generations. In particular, political participation among young women has jumped, breaking a historical trend in which young men were more likely to vote. Living in an age of political polarization has motivated this cohort to participate in the political process. A survey conducted before the 2020 U.S. presidential election by Barnes and Noble Education on 1,500 college students nationwide found that just one third of respondents believe who they vote for is "private information" and three quarters of them find it difficult to find unbiased news sources. 2018 was the first year when the majority of voters aged 18 to 24 were members of Generation Z, and they cast 4% of the votes. During the 2020 U.S. presidential election, Millennials and Generation Z voted for Joe Biden by a margin of 20 percentage points. Generation Z cast 8% of the votes that year. High youth turnout was a factor behind Biden's victory. Yet, young people's support for him fell quickly afterwards. By late 2021, only 29% of adults in this age group approved of his performance as president whereas 50% disapproved, a gap of 21 points, the largest of all age groups. In the 2022 midterm election, voters below the age of 30 were the only major age group supporting the Democratic Party, but their numbers still were large enough to prevent Republicans from controlling the majority of seats in the Senate.
2011: Icon acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management 2012: Icon acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits 2013: Icon acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services 2014: Icon acquired Aptiv Solutions, a market leader in adaptive trial design and execution 2015: Icon acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US 2016: Icon acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market 2017: Icon acquired MAPI Group, thereby becoming the world's second-largest provider of late-phase services 2019: Icon acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry 2020: Icon acquired MedPass International, a leading European medical device CRO, regulatory and reimbursement consultancy 2021: Icon acquired PRA Health Sciences, a competitor offering clinical research services, for US$12 billion.
=== Total chemical synthesis === A complete organic synthesis pathway for the pyoverdine produced by P. aeruginosa strain PAO1 has been reported using solid-phase peptide synthesis. This protocol yielded pyoverdine at high yield (~48%) and is expected to substantially increase the ability of scientists to generate targeted derivatives on the pyoverdine scaffold and to facilitate the creation of siderophores with antimicrobial warheads.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.